On Location ASH Meeting on Hematologic Malignancies
malignancies – over the meeting’s three days.
Personally, I think all of the sessions are
essential in order to truly stay up-to-date on
the medical advances and how to deliver the
best care to your patients.
The ASH Meeting on Hematologic Malignancies is accepting submissions for peer-reviewed abstracts and posters to be presented
at the meeting — what can attendees expect
from the abstract and poster presentations?
Dr. Connors: There is a continually emerging
evidence base in hematologic malignancies
and we hope that people will bring insights to
this meeting that will help us advance past the
current evidence. The current evidence base
is generally inadequate for all the potential
questions regarding treatment and patient
management that will arise.
Dr. Anderson: Our hope is that trainees and
early clinical researchers will present cutting-
edge findings in the poster sessions. On
top of that, I think the posters offer a good
opportunity to meet with the studies’ primary
investigators to discuss results and interact
with those researchers.
Dr. Tallman: We’d also like to emphasize to
people who are considering submission of
an abstract or poster that they may submit
the identical abstract to this meeting and
the 2015 ASH Annual Meeting – and that
ELOCTATE
THE FIRST AND ONLY rFVIII
WITH A PROLONGED HALF-LIFE
5 DAYS WITH
FACTOR LEVELS ABOVE 1%
Mean Plasma FVIII Activity (IU/dL)
MEAN FACTOR ACTIVITY PROFILE
AFTER A SINGLE DOSE (50 IU/kg)†
MEAN FACTOR ACTIVITY PROFILE AFTER A SINGLE DOSE (50 IU/kg)*
100
50
MEAN TERMINAL HALF-LIFE
AFTER A SINGLE 5O IU/kg
DOSE IN ADULTS*†
10
5
19.7
HOURS
(17.4, 22.0)
ABOVE
1
0
20
40
60
80
Time (Hours)
100
120
Mean terminal half-life after a single 50 IU/kg
dose in pediatric and adolescent patients*†‡
• 16.4 (14.1, 18.6) hours in subjects 12 to 17 (n=11)
• 14.6 (11.5, 17.7) hours in subjects 6 to 11 (n=27)
• 12.0 (9.55, 14.4) hours in subjects 2 to 5 (n=10)
1%
*The pharmacokinetics of ELOCTATE were evaluated following a
single dose of 50 IU/kg in the Phase 3 study of 28 adults and 11
adolescent, previously treated patients (ages 12 to 17 years), and in
an open-label, multicenter study of 37 pediatric, previously treated
patients (ages 2 to 5 years and 6 to 11 years).
†
Presented in arithmetic mean (95% CI).
‡
Compared to adults and adolescents, clearance was higher in
children 2 to 5 years of age, indicating a need for dose adjustments.
For patients 6 years and older, dose adjustment is not required.
Selected Important Safety Information
• Hypersensitivity reactions, including anaphylaxis, are possible with ELOCTATE. Immediately
discontinue ELOCTATE and initiate appropriate treatment if hypersensitivity reactions occur
Please see Brief Summary of full Prescribing Information on the following pages.
This information is not intended to replace discussions with your healthcare provider.